| Fairmount Funds Management LLC |
| 3.7M |
| $352.6M |
| 0.0% |
| 6.143% |
| 23.31% |
| 5 | Capital World Investors | 3.4M | $323.7M | — | 5.640% | 0.04% |
| 6 | RTW INVESTMENTS, LP | 3.1M | $298.7M | +52.5% | 5.205% | 2.55% |
| 7 | STATE STREET CORP | 2.7M | $254.4M | +65.7% | 4.432% | 0.00% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $224.7M | +27.0% | 3.915% | 0.00% |
| 9 | Paradigm Biocapital Advisors LP | 2.1M | $204.1M | -7.6% | 3.556% | 3.82% |
| 10 | Deep Track Capital, LP | 1.9M | $183.3M | -5.3% | 3.193% | 2.67% |
| 11 | Bellevue Group AG | 1.7M | $157.7M | +226.9% | 2.748% | 3.32% |
| 12 | FRANKLIN TEMPLETON INC | 1.6M | $154.3M | +61.5% | 2.688% | 0.03% |
| 13 | Remedium Capital Partners, LLC | 1.6M | $149.0M | 0.0% | 2.596% | 32.99% |
| 14 | RA CAPITAL MANAGEMENT, L.P. | 1.6M | $148.0M | — | 2.578% | 1.29% |
| 15 | VIKING GLOBAL INVESTORS LP | 1.5M | $143.1M | -43.6% | 2.493% | 0.41% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.4M | $136.1M | +49.8% | 2.371% | 0.01% |
| 17 | Jupiter Topco LLC | 1.4M | $131.0M | — | 2.281% | 0.05% |
| 18 | PERCEPTIVE ADVISORS LLC | 1.3M | $128.0M | -3.6% | 2.230% | 1.92% |
| 19 | Polar Capital Holdings Plc | 1.2M | $116.9M | +17.3% | 2.037% | 0.28% |
| 20 | CITADEL ADVISORS LLC | 1.2M | $109.7M | +13.2% | 1.911% | 0.01% |
| 21 | BNP PARIBAS FINANCIAL MARKETS | 1.1M | $102.7M | +9773.9% | 1.789% | 0.04% |
| 22 | Avidity Partners Management LP | 760K | $72.4M | 0.0% | 1.261% | 11.59% |
| 23 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 658K | $62.7M | — | 1.091% | 1.10% |
| 24 | Aberdeen Group plc | 647K | $61.6M | +754.8% | 1.073% | 0.09% |
| 25 | UBS Group AG | 639K | $60.8M | +201.2% | 1.060% | 0.01% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ORKA — a direct measure of their conviction.
| 52.69% |
| +1.23 pp |
| $320M |
| 45% |
| Q4 2024 | 67 | +60% | 51.46% | +10.74 pp | $579M | 3.0% |
| Q3 2024 | 42 | — | 40.72% | — | $597M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
96 institutions opened new positions in ORKA during Q2 2026, while 25 fully exited. 145 added to existing positions and 11 trimmed.
ORKA institutional ownership rose by 37.03 percentage points quarter-over-quarter, with a net change of +73 holders.
The top 10 institutions account for 52.2% of all reported 13F value in ORKA, and the top 25 account for 77.6%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.